Access to health

Every person has a fundamental right to health. This is the underlying premise of our efforts to improve availability, accessibility, affordability and quality of care. We also seek to contribute to the United Nations Millennium Development Goals, which address key challenges to overcome by 2015. These challenges include reducing child mortality, improving maternal health and combating diseases hampering social and economic development.

The goal of our long-term efforts is to generate the greatest health impact for people with diabetes and haemophilia, improve access to care for the most vulnerable and work in partnerships to build healthcare system capacity. We want to effect change in areas that affect current and future generations, with a long-term impact consistent with our role as a sustainable business.


Foundation support
Part of our contribution to improving access to health is our continued long-term financial commitment to the World Diabetes Foundation (WDF). In 2002 and 2008 our shareholders voted to contribute a portion of net insulin sales to the WDF over 10 years. These donations are reported annually on our income statement.

Affordability of insulin in least developed countries
The cost of therapy still constitutes a significant barrier for better healthcare in low income countries. Through our long-standing differential pricing policy we sell insulin at or below 20% of the average prices for insulin in the Western world, in this case Europe (EU, Switzerland and Norway), the United States, Canada and Japan.

Changing Diabetes® in Children programme
Today, there are 480,000 children under the age of 15 years with type 1 diabetes in the world. About half of these children live in resource-poor settings, often without necessary diabetes treatment facilities. Children with type 1 diabetes have high mortality rates, with life expectancies of less than one year in some countries in sub-Saharan Africa. This is the result of poor accessibility and affordability of medicines and diabetes care, especially in rural areas.

Changing Diabetes® in Pregnancy
Worldwide, about 10 million women every year develop gestational diabetes affecting up to 15% of pregnant women. Correct treatment and lifestyle education effectively reduces both the immediate and long-term risks to mother and baby. But many cases of gestational diabetes mellitus (GDM) are undiagnosed, and most are in low- and middle-income countries. In response, Novo Nordisk has developed its Changing Diabetes® in Pregnancy programme to spread understanding of how diabetes in pregnancy needs to be identified, and how it can be controlled with lifestyle advice.

Base of the pyramid
In 2011, Novo Nordisk established a corporate innovation project to address the needs of people with diabetes living at the base of the pyramid (BOP). This patient-centred project aims to deliver profitable, sustainable and scalable solutions to provide diabetes care to a large segment of people earning between 1,500 US dollars and 3,000 dollars annually.

Compare us with others – Global Reporting Initiative


Our workforce grew by 7%, while sales grew 9% in DKK


Waste increased by 61%, see why


Balance sheets and more since 2005 – download in excel


Download or order Annual Report 2011